TORPEdO：一项关于调强质子束治疗与调强放射治疗对比以降低口咽癌多种毒性的III期试验。
TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer.
作者信息
Thomson David J, Cruickshank Clare, Baines Helen, Banner Russell, Beasley Matthew, Betts Guy, Bulbeck Helen, Charlwood Frances, Christian Judith, Clarke Matthew, Donnelly Olly, Foran Bernadette, Gillies Callum, Griffin Clare, Homer Jarrod J, Langendijk Johannes A, Lee Lip Wai, Lester James, Lowe Matthew, McPartlin Andrew, Miles Elizabeth, Nutting Christopher, Palaniappan Nachi, Prestwich Robin, Price James M, Roberts Clare, Roe Justin, Shanmugasundaram Ramkumar, Simões Rita, Thompson Anna, West Catharine, Wilson Lorna, Wolstenholme Jane, Hall Emma
机构信息
The Christie NHS Foundation Trust, Manchester, United Kingdom.
The Institute of Cancer Research, London, United Kingdom.
出版信息
Clin Transl Radiat Oncol. 2022 Nov 21;38:147-154. doi: 10.1016/j.ctro.2022.11.010. eCollection 2023 Jan.
•There is a lack of prospective level I evidence for the use of PBT for most adult cancers including oropharyngeal squamous cell carcinoma (OPSCC).•TORPEdO is the UK's first PBT clinical trial and aims to determine the benefits of PBT for OPSCC.•Training and support has been provided before and during the trial to reduce variations of contouring and radiotherapy planning.•There is a strong translational component within TORPEdO. Imaging and physics data along with blood, tissue collection will inform future studies in refining patient selection for IMPT.
•对于包括口咽鳞状细胞癌（OPSCC）在内的大多数成人癌症，使用质子束治疗（PBT）缺乏前瞻性I级证据。
•TORPEdO是英国首个PBT临床试验，旨在确定PBT对OPSCC的疗效。
•在试验前和试验期间提供了培训和支持，以减少轮廓勾画和放射治疗计划的差异。
•TORPEdO中有一个强大的转化研究部分。影像学和物理数据以及血液、组织采集将为未来优化调强质子治疗（IMPT）患者选择的研究提供信息。
Zotero 插件